Oculis Holding AG (OCS)
Energy
$13.18+0.69%Close
BUYRECOVERY · day 15
$13.18+0.69%
Key stats
- Market cap
- $753M
- Avg volume
- 591.5K
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
First Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
Does Oculis Holding AG (OCS) Have the Potential to Rally 187.83% as Wall Street Analysts Expect?
Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis' Position as an Emerging Leading Neuro-Ophthalmology Company
Oculis Holding AG (OCS) Reports Q2 Loss, Tops Revenue Estimates
Oculis Reports Q2 2026 Financial Results and Provides Company Update
Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses
Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses
Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses
OCS Group to buy Mitie for $4.17 billion
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCS
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCS
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCS
OCS Investors Have Opportunity to Join Oculis Holding AG Fraud Investigation with the Schall Law Firm
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCS
OCS Investors Have Opportunity to Join Oculis Holding AG Fraud Investigation with the Schall Law Firm
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCS
Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026
